Immediate Impact
1 from Science/Nature 84 standout
Citing Papers
Toward personalized treatment approaches for non-small-cell lung cancer
2021 Standout
Small molecules, big impact: 20 years of targeted therapy in oncology
2020 Standout
Works of V.R. Archer being referenced
Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704
2007
Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens
2005
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| V.R. Archer | 265 | 242 | 54 | 74 | 14 | 343 | |
| Humera Khurshid | 130 | 179 | 76 | 67 | 24 | 323 | |
| Väinämö Nikkanen | 203 | 183 | 72 | 52 | 13 | 378 | |
| S.B. Kaye | 145 | 258 | 53 | 86 | 13 | 406 | |
| J.W.G. van Putten | 220 | 212 | 28 | 67 | 11 | 387 | |
| Jeffrey M. Crane | 277 | 150 | 34 | 145 | 10 | 352 | |
| Christopher Hocking | 178 | 170 | 84 | 103 | 15 | 320 | |
| Samer Tabchi | 135 | 209 | 20 | 64 | 23 | 315 | |
| Huub Belderbos | 221 | 116 | 31 | 60 | 17 | 320 | |
| A. Iop | 149 | 274 | 60 | 50 | 21 | 362 | |
| Alison Norton | 312 | 299 | 25 | 44 | 10 | 409 |
All Works
Loading papers...